用于视网膜疾病的抗血管生成分子治疗的递送。

Delivery of anti-angiogenic molecular therapies for retinal disease.

机构信息

UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V9EL, United Kingdom.

出版信息

Drug Discov Today. 2010 Apr;15(7-8):272-82. doi: 10.1016/j.drudis.2010.02.004. Epub 2010 Feb 23.

DOI:10.1016/j.drudis.2010.02.004

PMID:20184967

Abstract

Angiogenic diseases of the retina are the leading cause of blindness in the developed world. The development of anti-angiogenic molecular therapies has transformed the prognosis of these conditions, especially age-related macular degeneration. With these new treatments comes the new challenge of delivering an effective dosage to the retina, over a prolonged period of time and in a safe and cost-effective manner. A range of new anti-angiogenics are on the horizon, offering new and varied modes of drug delivery. In addition, a range of new sustained-release drug delivery technologies are being developed.

摘要

视网膜血管疾病是发达国家致盲的主要原因。抗血管生成的分子治疗方法的发展改变了这些疾病的预后，特别是年龄相关性黄斑变性。随着这些新的治疗方法的出现，需要以安全且具有成本效益的方式，在较长时间内将有效剂量递送至视网膜，这带来了新的挑战。一系列新的抗血管生成药物正在出现，提供了新的、不同的药物输送方式。此外，还在开发一系列新的缓释药物输送技术。